Pharmaceutical Executive
August 01, 2004
Features
Pediatric drugs require investments in formulation, but the market opportunity is worth the cost.
August 01, 2004
Features
Backlash from a government VNR provides lessons for pharma PR.
August 01, 2004
Features
We had a vision that this project deserved a company with a focus on HDL as the next frontier in the cardiovascular area.
August 01, 2004
Features
Blockbusters may not grow on trees, but sometimes they hide in desk drawers. At least that's how it was for one of pharma's most enduring brands--one which, near the end of its patent life, boasts 16 indications, four formulations, and three (recent) billion-dollar years in a row.